一、研究所介绍
山东第一医科大学医学科技创新中心转化医学研究所以临床医学与基础医学结合转化的科研范式为核心，源于临床，专于探索，交叉融通，回归临床。研究所依托医学科技创新中心科研平台以及山东省临床优势资源，以临床科学问题为导向，聚焦前沿临床问题，整合基础研究资源，突破理论研究瓶颈，实现临床治疗指导和应用转化。目前研究所有独立团队12个。其中国家级青年人才称号2人，山东省“泰山学者”岗位专家8人。涉及领域涵盖内科、外科、肿瘤、感染免疫、心血管、药物药理等专业，团队学科带头人均有丰富的临床诊疗经验以及基础医学研究经历。
二、研究领域
研究方向涉及临床代谢性疾病、消化系统、循环系统疾病以及肿瘤的诊疗等。例如：慢性肾脏病与糖尿病肾病；慢性代谢性疾病分子标志物的筛查和分子机制研究；血液系统疾病；细胞外囊泡与免疫代谢疾病以及基于外囊泡作为药物载体的精准靶向治疗；胰腺炎、消化道肿瘤发生发展机制及诊治策略方面的基础和转化；糖尿病与脂代谢紊乱，以及肿瘤早诊早治、干细胞治疗和转化医学等。
三、课题组
四、研究成果介绍
（一）项目、论文、获奖等情况概述
研究所自成立以来，获得国家自然科学基金重点项目1项，国家自然科学基金区域联合基金重点项目1项，面上及青年基金项目31项，以及多项省市级科研项目，发表多篇包括Cell Metabolism, Nature Metabolism, Hepatology, Journal of Hepatology, Cell Research, Cell Death & Disease, Redox Biology等在内的多篇高水平研究论文。
（二）代表性成果
1.Yao Z, Gong Y, Chen W, Shao S, Song Y, Guo H, Li Q, Liu S, Wang X, Zhang Z, Wang Q, Xu Y, Wu Y, Wan Q, Zhao X, Xuan Q, Wang D, Lin X, Xu J, Liu J, Proud CG, Wang X, Yang R, Fu L, Niu S, Kong J, Gao L, Bo T, Zhao J. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. Nat Metab. 2023 Oct;5(10):1706-1725. doi: 10.1038/s42255-023-00896-7. Epub 2023 Sep 21.
2.Fan X, Han J, Zhao E, Fang J, Wang D, Cheng Y, Shi Y, Wang Z, Yao Z, Lu P, Liu T, Li Q, Poulsen KL, Yuan Z, Song Y, Zhao J. The effects of obesity and metabolic abnormalities on severe COVID-19-related outcomes after vaccination: A population-based study. Cell Metab. 2023 Apr 4;35(4):585-600.e5. doi: 10.1016/j.cmet.2023.02.016. Epub 2023 Mar 1.
3.Song Y, Liu J, Zhao K, Gao L, Zhao J. Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases. Cell Metab. 2021 Oct 5;33(10):1911-1925. doi: 10.1016/j.cmet.2021.09.001. Epub 2021 Sep 24.
4.Fan X, Shi Y, Han J, Song Y, Zhao J. Beyond body weight: Diversified presentation of MASLD in lean, overweight, and obese participants. J Hepatol. 2024 Apr;80(4):e147-e150. doi: 10.1016/j.jhep.2023.11.015. Epub 2023 Nov 28.
5.Guo Y, Zhao M, Bo T, Ma S, Yuan Z, Chen W, He Z, Hou X, Liu J, Zhang Z, Zhu Q, Wang Q, Lin X, Yang Z, Cui M, Liu L, Li Y, Yu C, Qi X, Wang Q, Zhang H, Guan Q, Zhao L, Xuan S, Yan H, Lin Y, Wang L, Li Q, Song Y, Gao L, Zhao J. Cell Res. 2019 Feb;29(2):151-166. doi: 10.1038/s41422-018-0123-6. Epub 2018 Dec 17. Blocking FSH inhibits hepatic cholesterol biosynthesis and reduces serum cholesterol.
6.Su H, Liu B, Chen H, et al. LncRNA ANRIL mediates endothelial dysfunction through BDNF downregulation in chronic kidney disease. Cell Death Dis. 2022;13(7):661. Published 2022 Jul 29. doi:10.1038/s41419-022-05068-1
7.Zhao Y, Fan X, Wang Q, et al. ROS promote hyper-methylation of NDRG2 promoters in a DNMTS-dependent manner: Contributes to the progression of renal fibrosis. Redox Biol. 2023;62:102674. doi:10.1016/j.redox.2023.102674
8.Hu J, Wang Q, Fan X, et al. Long noncoding RNA ENST00000436340 promotes podocyte injury in diabetic kidney disease by facilitating the association of PTBP1 with RAB3B. Cell Death Dis. 2023;14(2):130. Published 2023 Feb 15. doi:10.1038/s41419-023-05658-7
9.Zihao Zhang,Hao Wu,Wei Chong,Liang Shang,Changqing Jing,Leping Li. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers. Cell Death Dis. 2022 Oct 27;13(10): 903. doi:10.1038/s41419-022-05350-2.
10.Hao Wu,Mengdi Fu,Jin Liu,Wei Chong,Zhen Fang,Fengying Du,Yang Liu,Liang Shang,Leping Li. The role and application of small extracellular vesicles in gastric cancer. Mol Cancer. 2021 Apr 29;20(1): 71. doi:10.1186/s12943-021-01365-z.
11.Wei Chong,Xingyu Zhu,Huicheng Ren,Chunshui Ye,Kang Xu,Zhe Wang,Shengtao Jia,Liang Shang,Leping Li,Hao Chen. Integrated multi-omics characterization of KRAS mutant colorectal cancer. Theranostics. 2022 ;12(11): 5138-5154. doi:10.7150/thno.73089.
12.Huaiping Cui,Han Li,Hao Wu,Fengying Du,Xiaozhou Xie,Shujie Zeng,Zihao Zhang,Kangdi Dong,Liang Shang,Changqing Jing,Leping Li. A novel 3'tRNA-derived fragment tRF-Val promotes proliferation and inhibits apoptosis by targeting EEF1A1 in gastric cancer. Cell Death Dis. 2022 May 18;13(5): 471. doi:10.1038/s41419-022-04930-6.
13.Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol. 2021 Aug 17;14(1):125. doi: 10.1186/s13045-021-01134-x.
